StemCo Biomedical

About StemCo Biomedical

StemCo Biomedical, Inc. is a life sciences company established in 1999 and situated in the Research Triangle Park area of North Carolina. The company was co-founded by Jonathan M Lawrie. StemCo Biomedical operates within the biotechnology sector, focusing on the development, manufacturing, and distribution of medical products designed to enhance the therapeutic transplantation of adult hematopoietic stem and progenitor cells.

The company's core business revolves around creating solutions that improve the outcomes of stem cell transplants derived from sources such as bone marrow, peripheral blood, and umbilical cord blood. It serves the medical and research markets by providing tools that address the critical need for more effective stem cell therapies. The business model appears to be transactional, involving the sale of hardware and software products to enterprise clients like research institutions and healthcare providers. The company operates in a market estimated to be over $1 billion annually.

StemCo Biomedical's product line is centered on technologies that identify, sort, and custom-engineer stem cell grafts. A key feature of its technology is the ability to select viable stem cells based on the cellular expression of Aldehyde Dehydrogenase (ALDH), a method intended to improve the quality and efficacy of the transplant. The ultimate benefit is to provide patients with more effective treatments, with long-term potential applications in treating autoimmune diseases. The company raised approximately $13.8 million across two funding rounds, with the last known round being a Series B for $9.8 million in March 2003.